- Stocks
- Pharma & Healthcare
- Shree Pacetroni
Shree Pacetroni share price
NSE: SHREEPACPharma & HealthcareMedical Instruments & Supplies
Shree Pacetroni at a glance
With a market capitalisation of ₹50 Cr, it ranks 3077th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Instruments & Supplies.
Its return on equity was 17.4% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹5 Cr (+25.5% year on year) and net profit ₹1 Cr (+146.7%), on a consolidated basis. Promoters held 36.44% of the company as of 30 Jun 2026; 9.44% of promoter shares were pledged.
Key numbers
- Market cap
- ₹50 CrRank 3077 on NSE
- Price to book
- 1.9×FY26
- EPS (TTM)
- ₹8.71to Q4 FY26
- ROE
- 17.4%FY26
- ROCE
- 25.0%FY26
- Debt to equity
- 0.15FY26
- Net profit margin
- 14.5%FY26
- Book value / share
- ₹48.30FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Shree Pacetroni quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹7 Cr | ₹4 Cr | ₹5 Cr |
| Revenue YoY | −17.2% | −22.8% | −15.6% | −35.6% | +10.1% | +63.1% | +19.3% | +25.5% |
| Net profit | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
| Net profit YoY | −57.0% | −95.5% | −127.5% | −68.5% | +78.4% | +4,266.7% | — | +146.7% |
| Net margin | 7.6% | 0.7% | −3.0% | 10.5% | 12.4% | 19.9% | 1.4% | 20.7% |
| EPS | ₹1.03 | ₹0.09 | −₹0.31 | ₹1.26 | ₹1.85 | ₹3.64 | ₹0.16 | ₹3.06 |
Shree Pacetroni financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹8 Cr | ₹9 Cr | ₹20 Cr | ₹22 Cr | ₹17 Cr | — |
| Operating profit | ₹0 Cr | ₹1 Cr | ₹5 Cr | ₹5 Cr | ₹1 Cr | — |
| Net profit | ₹0 Cr | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹1 Cr | — |
| EPS (₹) | ₹0.00 | ₹2.00 | ₹9.00 | ₹9.00 | ₹2.00 | — |
| Cash from operations | ₹1 Cr | ₹2 Cr | ₹2 Cr | −₹0 Cr | −₹0 Cr | — |
| Total debt | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹6 Cr | ₹6 Cr | ₹10 Cr | ₹13 Cr | ₹14 Cr | ₹18 Cr |
Shree Pacetroni shareholding pattern
| Holder | 30 Sep 2025 | 27 Nov 2025 | 31 Dec 2025 | 28 Mar 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 24.25% | 25.80% | 25.80% | 31.70% | 31.70% | 36.44% |
| Non-institutions | 75.61% | 74.07% | 74.06% | 68.30% | 68.30% | 63.56% |
| Promoter shares pledged | 14.78% | 13.61% | 13.60% | 10.85% | 10.85% | 9.44% |
Shree Pacetroni vs peers
The listed Pharma & Healthcare companies nearest to Shree Pacetroni by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| BANDARAMBandaram Pharma | — | — | — | ₹53 Cr | — | — |
| VRLVasundhara Ras | — | — | — | ₹53 Cr | — | — |
| VIVIMEDLABVivimed Labs | ₹6.21 | −1.90% | −45.8% | ₹51 Cr | — | — |
| SHREEPACShree Pacetroni | — | — | — | ₹50 Cr | — | — |
| BIOFILCHEMBiofil Chemicals & Pharmaceuticals | ₹30.00 | +2.15% | −27.3% | ₹49 Cr | 17.5 | — |
| SHANMUGAShanmuga Hospit | — | — | — | ₹48 Cr | — | — |
| MANGALAMMangalam Drugs And Organics | ₹29.66 | −3.07% | −58.5% | ₹47 Cr | — | — |
Ask anything about Shree Pacetroni
Pivot answers on the live chart with evidence you can check, and tests strategies against SHREEPAC's own history. Try: “Why has SHREEPAC moved over the last three months?” · “Backtest a 50-day moving-average crossover on SHREEPAC over five years” · “Compare SHREEPAC with BANDARAM on margins and valuation”
Frequently asked questions about Shree Pacetroni
What is the market cap of Shree Pacetroni?
Shree Pacetroni's market capitalisation is ₹50 Cr (₹50 Cr) at the 22 Oct 2026 close, ranking 3077th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Shree Pacetroni?
Return on equity was 17.4% in FY26 and return on capital employed was 25.0% in FY26 (consolidated figures).
Is Shree Pacetroni a debt-free company?
No. Shree Pacetroni's debt-to-equity ratio was 0.15 in FY26, with total debt of ₹0 Cr.
What were Shree Pacetroni's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Shree Pacetroni reported revenue of ₹5 Cr, +25.5% year on year, and net profit of ₹1 Cr, +146.7% year on year.
What is the shareholding pattern of Shree Pacetroni?
As of 30 Jun 2026: promoters 36.44%, non-institutions 63.56%. 9.44% of promoter shares were pledged.
Who are Shree Pacetroni's competitors?
The listed Pharma & Healthcare companies closest to Shree Pacetroni by market cap are Bandaram Pharma, Vasundhara Ras, Vivimed Labs, Biofil Chemicals & Pharmaceuticals, Shanmuga Hospit and Mangalam Drugs And Organics.
Is Shree Pacetroni a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Shree Pacetroni's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SHREEPAC against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text